AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16105981 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 1500
Study 11967671 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral laparoscopic hernia repair (TAPP)
Number of subjects: 1336
Study 11967671 — intervention group
Group type: COMPARATOR
Intervention: Unilateral laparoscopic hernia repair (TAPP)
Number of subjects: 1336
Study 10808386 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL from s.A (lung segment with most extensive involvement)
Number of subjects: 28
Study 10808386 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL from s.B (lung segment with least extensive involvement)
Number of subjects: 28
Study 10808386 — intervention group
Group type: COMPARATOR
Intervention: BAL from s.A and s.B in RD group
Number of subjects: 28
Study 10808386 — intervention group
Group type: COMPARATOR
Intervention: BAL from s.A and s.B in controls
Number of subjects: 28
Study 7775675 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic toothbrush
Number of subjects: 80
Study 7775675 — intervention group
Group type: COMPARATOR
Intervention: Control toothbrush
Number of subjects: 80
Study 2182578 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 2182578 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (included in some trials)
Number of subjects: 0
Study 7000250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin injection before operation and antibiotic capsules after operation
Number of subjects: 0
Study 7000250 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection and antibiotic capsules
Number of subjects: 0
Study 7000250 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection and placebo capsules
Number of subjects: 0
Study 7000250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin injection before operation
Number of subjects: 0
Study 7000250 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic injection
Number of subjects: 0
Study 31126265 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation programs
Number of subjects: 40
Study 31126265 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking
Number of subjects: 40
Study 31126265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in reducing smoking
Number of subjects: 40
Study 27997703 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine administered on day 1 of chemotherapy (n=43)
Number of subjects: 97
Study 27997703 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine administered on day 11 of chemotherapy (n=54)
Number of subjects: 97
Study 26176535 — intervention group
Group type: COMPARATOR
Intervention: Control arm of cluster randomised controlled trials
Number of subjects: 58601
Study 22576325 — intervention group
Group type: EXPERIMENTAL
Intervention: FS - composite resin Filtek Supreme Plus (3M/ESPE)
Number of subjects: 12
Study 22576325 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC + FS - resin-modified glass ionomer cement Vitrebond Plus (3M/ESPE) + FS
Number of subjects: 12
Study 22576325 — intervention group
Group type: EXPERIMENTAL
Intervention: FFS + FS - flowable composite resin Filtek Supreme Plus Flowable (3M ESPE) + FS
Number of subjects: 12
Study 22576325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aging)
Number of subjects: 12
Study 22576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Aging - Thermal/Mechanical cycling (3,000 cycles, 20‐80 °C/500,000 cycles, 50 N)
Number of subjects: 12
Study 21729116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride drops orally at a dose of 0.7 mg/kg
Number of subjects: 69
Study 19247684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic trabeculoplasty (PNT)
Number of subjects: 18
Study 19247684 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 18
Study 16938719 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture and moxa (TCM group, n = 15)
Number of subjects: 29
Study 16938719 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control group, CG, n = 14)
Number of subjects: 29
Study 15292806 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based computer-assisted surgery system
Number of subjects: 78
Study 15292806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cusum technique for evaluation
Number of subjects: 78
Study 11374408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g b.i.d.
Number of subjects: 221
Study 11374408 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1-2 mg/kg
Number of subjects: 221
Study 11374408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 221
Study 11374408 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 221
Study 9243683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine, 3 mg.kg‐1, diluted to 2 ml with saline, 1 ml per naris
Number of subjects: 40
Study 9243683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasal saline, 2 ml, 1 ml per naris)
Number of subjects: 40
Study 8467340 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 30
Study 8467340 — intervention group
Group type: COMPARATOR
Intervention: Non-Continuous Passive Motion (non-CPM)
Number of subjects: 30
Study 2830047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (1 mg)
Number of subjects: 12
Study 2830047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 mg)
Number of subjects: 12
Study 2830047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 12
Study 2830047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 12
Study 2830047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29699964 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session, Web-based parenting intervention
Number of subjects: 349
Study 29699964 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 349
Study 27031035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Strategy (SHS)
Number of subjects: 20
Study 27031035 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep Hygiene Strategy (NSHS)
Number of subjects: 20
Study 24925006 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin for inhalation (250 mg twice a day)
Number of subjects: 40
Study 24925006 — intervention group
Group type: COMPARATOR
Intervention: Taste-matched placebo
Number of subjects: 40
Study 23388602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton in infusions and then in tablets (cavinton forte)
Number of subjects: 661
Study 23388602 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without cavinton
Number of subjects: 661
Study 20921122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation of the nucleus accumbens
Number of subjects: 16
Study 20921122 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 16
Study 20921122 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 17945482 — intervention group
Group type: EXPERIMENTAL
Intervention: SU11248 (sunitinib malate)
Number of subjects: 0
Study 17450677 — intervention group
Group type: COMPARATOR
Intervention: IL-1 beta antagonist (single intraarticular injection of 50 or 150 mg)
Number of subjects: 0
Study 17450677 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 beta antagonist (150 mg)
Number of subjects: 0
Study 17450677 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha therapy
Number of subjects: 0
Study 12755009 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 12755009 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-II receptor blockers
Number of subjects: 0
Study 12755009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists
Number of subjects: 0
Study 10871968 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline depressive symptoms
Number of subjects: 5201
Study 8901169 — intervention group
Group type: EXPERIMENTAL
Intervention: contextually-based analogical reasoning problems
Number of subjects: 10
Study 8901169 — intervention group
Group type: COMPARATOR
Intervention: standardised test analogy items
Number of subjects: 10
Study 1293252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 80
Study 1293252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 6331100 — intervention group
Group type: EXPERIMENTAL
Intervention: calendar prompt and home‐based attendance contract intervention (Experimental group, N = 25)
Number of subjects: 50
Study 6331100 — intervention group
Group type: COMPARATOR
Intervention: standard aftercare treatment arrangements (Control group, N = 25)
Number of subjects: 50
Study 30957402 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBIRTH intervention (enhanced women-centred care)
Number of subjects: 0
Study 30957402 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 0
Study 30157824 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sacral nerve stimulation (SNM) with Medtronic PrimeAdvanced Surescan 97,702 Neurostimulator
Number of subjects: 60
Study 30157824 — intervention group
Group type: COMPARATOR
Intervention: Standard care for neurogenic bladder (NGB) including anticholinergic medications and usual bladder management strategies
Number of subjects: 60
Study 30157824 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sacral nerve stimulation (SNM)
Number of subjects: 60
Study 30157824 — intervention group
Group type: COMPARATOR
Intervention: Standard care for neurogenic bladder (NGB)
Number of subjects: 60
Study 26756747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/Timolol Fixed Combination (DTFC)
Number of subjects: 44
Study 26756747 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 44
Study 25175099 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (150 mg/day erlotinib + 15 mg/kg bevacizumab every 3 weeks)
Number of subjects: 154
Study 25175099 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone (150 mg/day)
Number of subjects: 154
Study 25175099 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 154
Study 25175099 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 154
Study 25175099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 21335480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist care program (regular drug-counseling sessions with pharmacists)
Number of subjects: 105
Study 21335480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist care program
Number of subjects: 105
Study 19411049 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Stamp Nutrition Education (FSNE)
Number of subjects: 219
Study 17457004 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental pulmonary vein antrum isolation using a larger Lasso catheter (25-30 mm in diameter)
Number of subjects: 187
Study 17457004 — intervention group
Group type: COMPARATOR
Intervention: Segmental pulmonary vein isolation using a regular Lasso catheter (15-20 mm in diameter)
Number of subjects: 187
Study 14667521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal W neobladder with serous lined extramural tunnel (group I)
Number of subjects: 60
Study 14667521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemi-Kock pouch with intussuscepted nipple valve (group II)
Number of subjects: 60
Study 14667521 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 11557704 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox) 50 U per axilla
Number of subjects: 307
Study 11557704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 11557704 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox)
Number of subjects: 307
Study 9564798 — intervention group
Group type: EXPERIMENTAL
Intervention: High starting dose of 1 mg budesonide twice daily followed by a stepwise decrease of 25% every second day for 1 week (group A)
Number of subjects: 42
Study 9564798 — intervention group
Group type: COMPARATOR
Intervention: Low dose of 0.25 mg budesonide twice daily for 1 week (group B)
Number of subjects: 42
Study 8171370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure polymethylmethacrylate
Number of subjects: 0
Study 8171370 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled bone
Number of subjects: 0
Study 8171370 — intervention group
Group type: EXPERIMENTAL
Intervention: Matchstick bone
Number of subjects: 0
Study 2741904 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal interview
Number of subjects: 216
Study 2741904 — intervention group
Group type: COMPARATOR
Intervention: Mailed self‐administered questionnaire
Number of subjects: 216
Study 31960447 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment containing 5% pyridine-2, 4-dicarboxylic acid diethyl ester and 0.25% resveratrol
Number of subjects: 79
Study 31533972 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy
Number of subjects: 398
Study 31533972 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in polysomnographic severity
Number of subjects: 398
Study 31533972 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 398
Study 27328649 — intervention group
Group type: EXPERIMENTAL
Intervention: High Cadence Training (HCT)
Number of subjects: 0
Study 27328649 — intervention group
Group type: COMPARATOR
Intervention: Low Cadence Training (LCT)
Number of subjects: 0
Study 25970339 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (BIS monitoring)
Number of subjects: 40
Study 25970339 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (Control - standard practice)
Number of subjects: 40
Study 23052571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg
Number of subjects: 19
Study 23052571 — intervention group
Group type: COMPARATOR
Intervention: Trazodone 25 mg
Number of subjects: 19
Study 23052571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23052571 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral performance
Number of subjects: 19
Study 21447078 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative paravertebral block
Number of subjects: 60
Study 21447078 — intervention group
Group type: COMPARATOR
Intervention: Postoperative paravertebral block
Number of subjects: 60
Study 19811459 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB)
Number of subjects: 617
Study 19811459 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment of bilirubin (VaB)
Number of subjects: 617
Study 16690128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.59-mg fluocinolone acetonide implant
Number of subjects: 278
Study 16690128 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.1-mg fluocinolone acetonide implant
Number of subjects: 278
Study 16690128 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow non-implanted eyes)
Number of subjects: 278
Study 16690128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.59-mg and 2.1-mg fluocinolone acetonide implants
Number of subjects: 278
Study 16287954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/d; n = 4439)
Number of subjects: 8888
Study 16287954 — intervention group
Group type: COMPARATOR
Intervention: Usual-dose simvastatin (20 mg/d; n = 4449)
Number of subjects: 8888
Study 16287954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/d)
Number of subjects: 8888
Study 16287954 — intervention group
Group type: COMPARATOR
Intervention: Usual-dose simvastatin (20 mg/d)
Number of subjects: 8888
Study 12221217 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SP) 40 g daily for 3 months
Number of subjects: 0
Study 12221217 — intervention group
Group type: COMPARATOR
Intervention: Milk-based protein (MP) 40 g daily for 3 months
Number of subjects: 0
Study 10211152 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus the social work intervention (n = 85)
Number of subjects: 162
Study 10211152 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 77)
Number of subjects: 162
Study 7605178 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric and eccentric contractions in patients with CLBP
Number of subjects: 48
Study 7605178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture with feet against the floor
Number of subjects: 48
Study 2136970 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with long-chain triglycerides (LCTs)
Number of subjects: 75
Study 2136970 — intervention group
Group type: COMPARATOR
Intervention: TPN with medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs)
Number of subjects: 75
Study 2136970 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with glucose-fat-based TPN (LCTs)
Number of subjects: 75
Study 2136970 — intervention group
Group type: COMPARATOR
Intervention: TPN with glucose-fat-based TPN (MCTs and LCTs)
Number of subjects: 75
Study 74730 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oestradiol in viscous gel
Number of subjects: 25
Study 74730 — intervention group
Group type: COMPARATOR
Intervention: Viscous gel alone
Number of subjects: 25
Study 31355775 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg
Number of subjects: 216
Study 31355775 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg
Number of subjects: 216
Study 28537062 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv (5.5 × 10^7 pfu, n=8)
Number of subjects: 19
Study 28537062 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv (2.2 × 10^8 pfu, n=7)
Number of subjects: 19
Study 28537062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=4)
Number of subjects: 19
Study 28537062 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 19
Study 25964839 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy (SWL)
Number of subjects: 206
Study 23553449 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (palpated pilot balloons of tracheostomy tube cuffs inflated to three different pressures)
Number of subjects: 49
Study 23553449 — intervention group
Group type: COMPARATOR
Intervention: Control group (viewed a video about inflating tracheostomy tube cuffs)
Number of subjects: 49
Study 23553449 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 49
Study 23553449 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 21807891 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus/MMF
Number of subjects: 150
Study 21807891 — intervention group
Group type: COMPARATOR
Intervention: tacrolimus/sirolimus
Number of subjects: 150
Study 21807891 — intervention group
Group type: COMPARATOR
Intervention: cyclosporine/sirolimus
Number of subjects: 150
Study 21807891 — intervention group
Group type: COMPARATOR
Intervention: sirolimus
Number of subjects: 150
Study 18842612 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (Pw)
Number of subjects: 0
Study 18842612 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with carboplatin
Number of subjects: 0
Study 18842612 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine with docetaxel (GDoc)
Number of subjects: 0
Study 18842612 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (Pw) vs GDoc
Number of subjects: 0
Study 16478772 — intervention group
Group type: EXPERIMENTAL
Intervention: High liver fat content (17.4 +/‐ 8.0%)
Number of subjects: 55
Study 16478772 — intervention group
Group type: COMPARATOR
Intervention: Low liver fat content (4.6 +/‐ 2.0%)
Number of subjects: 55
Study 15243470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg, PILO, n=29)
Number of subjects: 58
Study 15243470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA, n=29)
Number of subjects: 58
Study 15243470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg, PILO)
Number of subjects: 58
Study 15243470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 58
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon induction therapy (Group A: 10 MU IntronA/day for 2 weeks, then 10 MU/2 days for 12 weeks)
Number of subjects: 373
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group B: 5 MU/day for 14 weeks)
Number of subjects: 373
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group C: 5 MU/2 days for 14 weeks)
Number of subjects: 373
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon induction therapy (Group A) in genotype 1 patients
Number of subjects: 373
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group B) in genotype 1 patients
Number of subjects: 373
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group C) in genotype 1 patients
Number of subjects: 373
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon induction therapy (Group A) in genotype 3a patients
Number of subjects: 373
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group B) in genotype 3a patients
Number of subjects: 373
Study 11679972 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon therapy (Group C) in genotype 3a patients
Number of subjects: 373
Study 9597561 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS formulation (75 mg)
Number of subjects: 24
Study 9597561 — intervention group
Group type: COMPARATOR
Intervention: IR formulation (75 mg)
Number of subjects: 24
Study 9597561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 24
Study 8169026 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream applied for 3 weeks
Number of subjects: 68
Study 8169026 — intervention group
Group type: COMPARATOR
Intervention: Untreated control arm
Number of subjects: 68